c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study

被引：0
|
作者：
Bar, J. [1 ]
Baijal, S. [2 ]
Luo, A. [3 ]
Zhang, N. [4 ]
Ratajczak, C. [5 ]
Ansell, P. J. [6 ]
Lu, S. [7 ]
Camidge, D. R. [8 ]
机构：
[1] Univ Hosp Birmingham, Sheba Med Ctr, Jusidman Canc Ctr, Ramat Gan, Israel
[2] NHS Fdn Trust, Med Oncol Dept, Birmingham, W Midlands, England
[3] AbbVie Inc, Oncol Stat, Chicago, IL USA
[4] AbbVie Inc, CDx Strategy & Precis Med, Chicago, IL USA
[5] AbbVie Inc, Oncol Early Dev, Chicago, IL USA
[6] AbbVie Inc, Precis Med Oncol, Chicago, IL USA
[7] Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[8] Univ Colorado, Med Oncol, Ctr Canc, Aurora, CO USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1379P
引用
收藏
页码：S866 / S866
页数：1
相关论文
共 50 条
  • [41] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Eng, C.
    Bendell, J. C.
    Bessudo, A.
    Gabrail, N. Y.
    Diamond, J.
    Pande, A. U.
    Gorbatchevsky, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [42] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Bessudo, A.
    Bendell, J. C.
    Gabrail, N.
    Kopp, M. V.
    Mueller, L.
    Hart, L. L.
    Vladimirov, V. I.
    Pande, A. U.
    Gorbatchevsky, I.
    Eng, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study
    Chai, Jie
    Wang, Longgang
    Liu, Luguang
    Liu, Bing
    Sun, Dong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study
    Chai, J.
    Wang, L.
    Liu, L.
    Liu, B.
    Sun, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S908 - S908
  • [45] Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression
    Sheng, Xinan
    Yang, Kaiwei
    Ji, Yongpeng
    Zhou, Li
    Zou, Benkui
    Huang, Hang
    Wang, Yonghua
    Bai, Xue
    Feng, Dan
    Yang, Yong
    Bian, Jiasheng
    Yu, Zhixian
    Niu, Haitao
    Du, Peng
    Fang, Jianmin
    He, Zhisong
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
    De Miguel, M.
    Yamamoto, N.
    Raimbourg, J.
    Cho, B. C.
    Gottfried, M.
    Stemmer, S. M.
    Goldman, J. W.
    Blaney, M. E.
    Jennaro, T.
    Vasilopoulos, A.
    Li, R. R.
    Freise, K. J.
    Aristide, M. R. Neagu
    Morrison-Thiele, G.
    Hunter, Z. N.
    Burns, M.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2024, 35 : S805 - S806
  • [47] Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol
    Osumi, Hiroki
    Ishizuka, Naoki
    Takashima, Atsuo
    Kumekawa, Yosuke
    Nakano, Daisuke
    Shiozawa, Manabu
    Denda, Tadamichi
    Sawada, Ryoichi
    Ouchi, Kota
    Wakatsuki, Takeru
    Narikazu, Boku
    Kato, Ken
    Yamaguchi, Kensei
    Shinozaki, Eiji
    BMJ OPEN, 2022, 12 (09):
  • [48] A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation
    Lee, D. H.
    Roohullah, A.
    Cho, B. C.
    Lee, S-H.
    Lemech, C.
    De Souza, P.
    Millward, M.
    Choi, J.
    Park, K. E.
    Kim, E.
    Kim, N. Y.
    Shin, Y. K.
    Han, J-Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1096 - S1096
  • [49] A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
    Yoshioka, H.
    Azuma, K.
    Yamamoto, N.
    Takahashi, T.
    Nishio, M.
    Katakami, N.
    Ahn, M. J.
    Hirashima, T.
    Maemondo, M.
    Kim, S. W.
    Kurosaki, M.
    Akinaga, S.
    Park, K.
    Tsai, C. M.
    Tamura, T.
    Mitsudomi, T.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2066 - 2072
  • [50] Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)
    Ding, K.
    Liu, Y.
    Chen, J.
    Ying, J.
    Xu, Q.
    Xu, D.
    Sun, L.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S440 - S440
12345